RHÖN-KLINIKUM AG

  • WKN: 704230
  • ISIN: DE0007042301
  • Land: Deutschland

Nachricht vom 17.08.2012 | 14:45

RHÖN-KLINIKUM AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


RHÖN-KLINIKUM AG 

17.08.2012 14:45

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


Notification according to section 26 para. 1 WpHG 

UBS AG, Zürich, Switzerland, notified us pursuant to section 25 WpHG and
pursuant to section 25a WpHG of the following:

(1) UBS AG notified us pursuant to section 25 WpHG of the following:

On 10 August 2012, UBS AG fell below the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 4.90% of the voting rights in
RHÖN-KLINIKUM AG (equals 6,775,230 voting rights).

From these voting rights a proportion of 2.91% (equals 4,015,830 voting
rights) is based on voting rights pursuant to sections 21, 22 WpHG and a
proportion of 2.00% (equals 2,759,400 voting rights) is based on
(financial/other) instruments pursuant to section 25 WpHG. From the voting
rights based on instruments pursuant to section 25 WpHG a proportion of
0.00% (equals 0 voting rights) is held indirectly. The exercise period of
the instruments pursuant to section 25 WpHG is at any time.

(2) UBS AG notified us pursuant to section 25a WpHG of the following:

On 10 August 2012, UBS AG fell below the threshold of 5% of the voting
rights of RHÖN-KLINIKUM AG, Salzburger Leite 1, 97616 Bad Neustadt a. d.
Saale, Germany. On that date, UBS AG held 4.91% of the voting rights in
RHÖN-KLINIKUM AG (equals 6,792,385 voting rights).

On that date, the composition of the voting rights held by UBS AG was as
follows:

A proportion of 2.91% (equals 4,015,830 voting rights) was based on voting
rights pursuant to sections 21, 22 WpHG.

A proportion of 2.00% (equals 2,759,400 voting rights) was based on
(financial/other) instruments pursuant to section 25 WpHG. From the voting
rights based on instruments pursuant to section 25 WpHG a proportion of
0.00% (equals 0 voting rights) is held indirectly.

A proportion of 0.01% (equals 17,155 voting rights) was based on
(financial/other) instruments pursuant to section 25a WpHG. From the voting
rights based on instruments pursuant to section 25a WpHG a proportion of
0.00% (equals 0 voting rights) is held indirectly. The (financial/other)
instruments pursuant to section 25a WpHG are described as
Equity Swaps with expiration date 4 February 2015.

Bad Neustadt a.d. Saale, 17 August 2012

The Board of Management

___________________________________________________________________________

Dr. Kai G. Klinger
Head of Investor Relations
RHÖN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Phone: +49 9771 65 - 1318
Fax: +49 9771 99 - 1736



17.08.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Internet:     www.rhoen-klinikum-ag.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

Syzygy AG: Aktie kaufen

Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.

Aktuelle Research-Studie

Orad Hi-Tec Systems Ltd

Original-Research: Orad Hi Tec Systems (von VEM Aktienbank AG): Kaufen

21. Mai 2013